Skip to content
Medical Health Aged Care

ONE WEEK TO GO until the Hunter Memory Walk & Jog!

Dementia Australia 2 mins read

With only a few sleeps to go walkers, joggers and runners are gearing up to participate in the 2024 Memory Walk & Jog in the Hunter.

More than 740 people have already signed-up to take part – but there’s always room for more with online registrations still open, or sign-up on the day of the event.  

Dementia Australia CEO Professor Tanya Buchanan said it is fantastic to see Hunter region locals throwing their support behind Memory Walk & Jog.

“As we prepare to host Memory Walk & Jog on Saturday 15 June at Speers Point Park, Speers Point for another successful year, we hope everyone will consider joining us,” Professor Buchanan said.

“It’s estimated that 65 per cent of people living with dementia live in the community. This could be a family member, a friend or a neighbour. It could be anyone in our community. By walking, jogging, or running, raising money and awareness, you will help the countless families impacted by dementia in the Hunter and across Australia.”

 

This event is the last of our 22 Memory Walk & Jog events held across Australia in 2024. Participants can register as an individual or an entire team, to remember a loved one, or in support of a loved one who is currently living with dementia. Each event offers a wonderful opportunity for people impacted by dementia and their supporters to come together, walk or run, at any fitness level, and to raise money and share stories.   

Walk or jog with us. We are in this together. 

 

Sign-up to walk, jog or run or join in as a Volunteer at www.memorywalk.com.au. Share your Memory Walk & Jog experience on your socials and Donate today to support people living with dementia across Australia. 

 

If you can’t attend an event, why not organise your own group or individual walk or jog, with a MyWay event. Choose your own date and location and register at www.memorywalk.com.au/get-involved/mw.

 

Dementia Australia spokespeople and a local case study are available for media stories. Please contact Ash Blakemore, Senior Media & Communications Advisor, 0448 170 672, ash.blakemore@dementia.org.au

 

Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.  

 

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au   

 

-Ends-

Media contacts: Ash Blakemore, Senior Media & Communications Advisor, 0448 170 672, ash.blakemore@dementia.org.au. Andrea Hogan, Media and Communications Manager, 0406 904 118, andrea.hogan@dementia.org.au

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors: Photos and video of previous Memory Walk & Jog events are available for publication.  

We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.

Media

More from this category

  • Medical Health Aged Care
  • 24/06/2024
  • 17:07
Takeda Pharmaceutical Company Limited

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase1 CMV Is One of the Most Common…

  • Contains:
  • CharitiesAidWelfare, Medical Health Aged Care
  • 24/06/2024
  • 16:20
National Rural Health Alliance

Community-led innovation to revolutionise healthcare access in rural Australia

The National Rural Health Alliance (the Alliance) is delighted that the Minister for Health and Aged Care, the Hon Mark Butler, has today announced…

  • Contains:
  • Business Company News, Medical Health Aged Care
  • 24/06/2024
  • 12:25
Jane Morgan Management

Imugene (ASX:IMU) Doses First Patient in Pioneering Phase 1 onCARlytics Trial

Sydney, Australia, 24 June 2024: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is thrilled to announce the dosing of the first patient in the intravenous (IV) infusion combination arm of its Phase 1 onCARlytics (CF33-CD19) clinical trial. This groundbreaking trial, named OASIS, is being conducted at City of Hope in California and is designed to transform the treatment landscape for patients with advanced solid tumors. The OASIS trial is a world-first, combining a CD19-expressing oncolytic virus with a CD19-targeting drug. The trial aims to recruit 40-45 patients with advanced solid cancers that have metastasized, with preliminary early combination data…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.